Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

If You Can't Beat Em'…Merck Signs Authorized Generic Deal For Zocor And Proscar

This article was originally published in The Pink Sheet Daily

Executive Summary

Dr. Reddy's will sell authorized generics of Zocor and Proscar upon expiration of their respective patents in June.

You may also be interested in...



Dr Reddy’s Launches Generic Versions Of GSK’s Imitrex; Ranbaxy May Have To Wait

MUMBAI - One more blockbuster drug will be available to U.S. citizens at a fraction of its brand price as India's Dr Reddy's announced the launch of generic versions of GlaxoSmithKline's anti-migraine drug Imitrex (sumatriptan)

Dr. Reddy’s Tops Billion Dollar Mark In First Nine Months Of Fiscal 2007

Indian generic drug maker achieved the milestone on acquisitions supported by a “strong and profitable” growth engine.

Dr. Reddy’s Tops Billion Dollar Mark In First Nine Months Of Fiscal 2007

Indian generic drug maker achieved the milestone on acquisitions supported by a “strong and profitable” growth engine.

Related Content

Topics

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel